Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

We spoke with Dr. Demetre Daskalakis, the director of the CDC’s National Center for Immunization and Respiratory Diseases, about the agency’s avian flu response.

Millions of Americans rely on a new class of medications to manage chronic conditions like diabetes and obesity, with ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

Left untreated, obstructive sleep apnea is linked to daytime sleepiness and an increased risk of anxiety, diabetes, ...

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Not everybody loses the same amount of weight on medications such as Ozempic and Saxenda—treatment indication, dosage, and ...

Those who took Ozempic or a similar drug had a 40% lower chance of overdosing on opioids and a 50% lower chance of getting ...

周四，Leerink Partners维持了对制药巨头礼来（NYSE:LLY）的"跑赢大市"评级和990.00美元的目标价。该公司的立场是基于英国最近的动向，英国计划评估礼来的药物tirzepatide对肥胖症造成的经济压力的影响。

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.

礼来是全球最有价值的医疗保健股票，市值超过8000亿美元。在过去12个月里，股价上涨了超过50%。尽管增长前景强劲，但投资者可能会对该股超过100倍的市盈率感到犹豫。